European regulators have backed generics to the blockbusters tafamidis and ruxolitinib, alongside riociguat, but patent and exclusivity barriers mean meaningful market entry may remain several years away.
European regulators have backed generics to the blockbusters tafamidis and ruxolitinib, alongside riociguat, but patent and exclusivity barriers mean meaningful market entry may remain several years away.